Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Cancer Epidemiology Biomarkers & Prevention

Urine Test for Diagnosing Colorectal Cancers in Low- and Middle-Income Countries

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAdeleye Abiodun AdeomiOAOlusegun AlatiseOOOlalekan Olasehinde

Discussion

Loading...

Member takes

Overview

Pilot controlled trial highlights a Point of Care test's validity in diagnosing colorectal cancers in at-risk adults, suggesting potential for better outcomes in low- and middle-income countries.

Key Points

  • Urine-based test shows high sensitivity of 94.5% for diagnosing colorectal cancers in at-risk individuals.
  • The study assessed a pilot controlled trial involving 72 participants, yielding a specificity of 81.58%.
  • Analyzed using a Point of Care biosensor connected to a smart device via Bluetooth, enhancing accessibility.
  • This promising approach may enable early diagnosis and improved treatment outcomes in low- and middle-income countries.

Cite This Study

Adeomi et al. (2025) studied this question.

synapsesocial.com/papers/6930dc81ea1aef094cca242ehttps://doi.org/10.1158/1538-7755.asgcr25-abstract-65
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Point-of-Care Urine Metabolomics Test to Diagnose Colorectal Cancers in Low- and Middle-Income Countries: A Pilot Controlled Trial in Southwestern Nigeria2025
  2. 2A Portable Colorimetric Biosensor Platform for Urinary Colorectal Cancer Biomarker Testing in Low-Resource Settings2026
  3. 3Abstract 1039: A novel serum lipidomics signature validated in a prospective multi-center trial enables accurate and low-cost CRC screening2024
  4. 4Abstract 2387: Colorectal cancer equity and impact (CLEAR-CRC): The colorectal cancer alliance's community-based model for advancing biomarker testing2026
  5. 5Abstract P34: EARLY DETECTION OF PANCREATIC CANCER USING A TARGETED URINARY METABOLITE PANEL2025